新西兰在2025年将资助的雌激素补丁改为Viatris' Estradiol TDP Mylan,以解决短缺问题。 New Zealand to switch funded estrogen patches to Viatris' Estradiol TDP Mylan in 2025 to fix shortages.

新西兰政府机构Pharmac计划从2025年7月1日起,将主要注资的Oestradicol补丁品牌改为Viatris' Estradiol TDP Mylan,以改善供应并解决影响约70 000人的短缺问题。 New Zealand's government agency, Pharmac, plans to switch the main funded brand of oestradiol patches to Viatris' Estradiol TDP Mylan starting July 1, 2025, to improve supply and address shortages affecting about 70,000 people. 新品牌将是2025年12月1日以来唯一的供资选项。 The new brand will be the only funded option from December 1, 2025. 虽然有些病人可能需要改变品牌,但临床顾问保证新的补丁在临床上可以接受,并将满足健康需要。 While some patients may need to change brands, clinical advisors assure that the new patch is clinically acceptable and will meet health needs.